Clover Health Investments Highlights Growth and Star Ratings

Clover Health Investments Corporation (Nasdaq: CLOV), a company focused on enhancing healthcare access for Medicare recipients, has shared insights following the release of the 2026 Star ratings by the Centers for Medicare and Medicaid Services (CMS). The star ratings are a crucial aspect as they will impact the payment structure for 2027. Clover’s PPO Medicare Advantage plans received a rating of 3.5 stars, while its HMO plans were rated at 4.0 stars.

Andrew Toy, the company’s CEO, expressed optimism, noting that their technology-centered care approach means that these star ratings don’t drive success like they might for other companies. He pointed out that enhancements in their Clover Assistant—a tool bolstered by AI—and increasing physician engagement on their platform might actually counterbalance the star ratings’ influence. “We’re designed to deliver substantial network benefits to our members, regardless of our ratings,” he stated, emphasizing a commitment to growth and profitability.

In the first half of 2025, which mirrors the upcoming pay year of 2027, Clover reported continued adjusted EBITDA profitability, achieving a revenue increase of 34% year over year and a 32% rise in membership.

The company also showcased its strong clinical performance metrics. Their PPO plan notably scored 4.72 on the HEDIS Clinical Quality Index, which is largely attributed to the effectiveness of the Clover Assistant. However, Clover Health expressed concern that its overall star rating doesn’t accurately reflect the quality of health outcomes for its members. They argue that the star rating system disproportionately emphasizes non-outcome metrics—like surveys regarding member experiences—over actual clinical results.

Toy remarked on the broader industry perspective, suggesting that it might be time for Congress and CMS to reassess how these Star Rating systems gauge quality and improvements that have real benefits for members’ health. He believes companies demonstrating tangible clinical outcomes should thrive, positioning Clover for that future.

Looking ahead, Clover expects sustained Medicare Advantage growth and profitability in 2026 and 2027. Key drivers for this expectation include:

• An extensive array of AI-driven features within its Clover Assistant platform.
• An increasing number of physicians adopting Clover Assistant technology to enhance care quality and health outcomes.
• A focus on member retention to ensure strong performance among new cohorts, transforming them into high-margin returning members.
• Optimization of operational efficiencies concerning variable and fixed expenses.

This announcement underlines Clover’s proactive stance in navigating the complexities of Medicare Advantage while striving to provide high-quality care to its members.